We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The AIDS Healthcare Foundation (AHF), which provides free antiretroviral (ARV) drugs through its clinics in India, China and Cambodia, has denounced Abbott Laboratories' decision to withdraw its applications for new HIV drugs in Thailand.
The FDA has approved Aurobindo Pharma's generic didanosine pediatric oral solution, 10 mg/mL, allowing the drug to be marketed in the U.S. and used in the President's Emergency Plan for AIDS Relief (PEPFAR).
Novartis' first-in-class hypertension treatment Tekturna and sanofi-aventis' weight-loss drug Acomplia are among several expected 2007 U.S. drug launches that are estimated to reach global blockbuster status, according to IMS Health.
The Geneva-based World Health Organization (WHO) has published guidelines for the cultivation and collection of Artemisia annua L., a medicinal plant that is the source of artemisinin, which is used to produce the most effective medicines for malaria.
Bio-Bridge Science announced it has entered into a cooperative agreement with the Chinese Academy of Medical Sciences to research and develop a human papillomavirus (HPV) polyvalent vaccine using a prokaryotic expression system.
Pfizer, the largest drug company in the world, has opened offices in Namibia and plans to launch a clinical trials laboratory there serving both Namibia and Botswana, the Namibia Economist reports.
Schering-Plough, based in the U.S., announced it will acquire Organon BioSciences, the human healthcare businesses of Akzo Nobel, for approximately $14.4 billion.
Ranbaxy Laboratories announced last week that its Romanian subsidiary, Terapia Ranbaxy, has won approval from European regulators to market 20 new products, which will be launched in the coming months.
Nutra Pharma announced that its drug-discovery division, ReceptoPharm, has signed an agreement with Chinese drugmaker NanoGene Biotechnology to develop ReceptoPharm's antiviral drug, RPI-MN, in China.